【what is the quietest 300 blackout suppressor】Takeda's third-quarter profit rises 28 percent on strong sales of main drugs
TOKYO (Reuters) - Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit,what is the quietest 300 blackout suppressor supported by strong sales of its drugs for bowel disease and multiple myeloma.
Profit reached 112.5 billion yen ($1.03 billion) in October-December, Japan's biggest drugmaker said in a stock exchange filing.
The company also maintained its full-year operating profit forecast at 268.9 billion yen. That compared with the 240.7 billion yen average of 10 analyst estimates compiled by Refinitiv.
Takeda completed a $59 billion deal to acquire peer Shire in January, joining the ranks of the world's biggest 10 drugmakers by sales - and also becoming one of the world's most indebted.
Proceeding with its plan to sell up to $10 billion in non-core assets to slash the debt, Takeda aims to focus on five key areas: oncology, gastroenterology, neuroscience, rare disease, and plasma derived therapies.
The drugmaker is also looking at vaccines as a potential core business. It said earlier this week its experimental dengue vaccine is safe and effective at preventing all four types of the mosquito-borne disease.
Takeda has already started divesting. It announced on Monday that it would sell a set of 21 assets, including its headquarters building in Osaka, and book about 38 billion yen in proceeds for the year through March.
During nine months ending in December, sales of Entyvio, a treatment for Crohn's disease and ulcerative colitis, hit 201 billion yen, up 34.4 percent on year. Ninlaro, which treats multiple myeloma, rose 34.5 percent.
Takeda does not disclose quarterly sales of each product.
(Reporting by Takashi Umekawa; Editing by Christopher Cushing)
View comments
下一篇:A Sliding Share Price Has Us Looking At Malibu Boats, Inc.'s (NASDAQ:MBUU) P/E Ratio
相关文章:
- Does Market Volatility Impact Axovant Gene Therapies Ltd.'s (NASDAQ:AXGT) Share Price?
- Stock Market News For Jan 2, 2019
- 12 Financial Mistakes Your Company Is Probably Making
- BRIEF-Xiamen Kehua Hengsheng To Change Company Name To Kehua Hengsheng Co Ltd
- Bank of Montreal: More Upside After a Significant Gain?
- US STOCKS-Wall St ekes out gains in rocky start to 2019
- U.S. wins WTO ruling on Chinese grains; decision may also affect India
- Does Cohu, Inc.’s (NASDAQ:COHU) P/E Ratio Signal A Buying Opportunity?
- Can Guess (GES) Keep the Earnings Surprise Streak Alive?
- Euro zone factories ended 2018 on a low note - PMI
相关推荐:
- Buying a House? 4 Things to Take Off Your Must-Have List Now
- PRESS DIGEST- British Business - Jan 3
- Is Shubhlaxmi Jewel Art Limited’s (NSE:SHUBHLAXMI) ROE Of 15% Impressive?
- PG&E must deal with problem that bankruptcy won't end: fires
- U.S. telehealth companies brace for demand spike as coronavirus spread accelerates
- An early gain on Wall Street fades by midday
- BRIEF-iDreamsky Technology Holdings Says Shenzhen iDreamsky Entertainment Entered Investment Agreement
- Saudi PIF entertainment company plans to build leisure complex in Riyadh
- MT Højgaard Holding A/S: Financial Calendar 2021
- Tesla and Akamai Technologies tumble while Cabot Oil rises
- Roche Gets Emergency FDA Approval For Covid-19 Antibody Test, Starts Shipping
- What Cineworld Group plc’s (LON:CINE) ROE Can Tell Us
- 20 Ways To Earn Extra Money Before Black Friday
- CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
- NetCents Technology Notches Record Transaction Volume, Again
- Sanoma Oyj: Managers' Transactions
- 3 Reasons Growth Investors Will Love Charles River (CRL)
- Did Apogee Enterprises, Inc.'s (NASDAQ:APOG) Recent Earnings Growth Beat The Trend?
- NYSE: REZI Shareholder Notice: Lawsuit against Resideo Technologies, Inc. announced by Shareholders Foundation
- Here's Why We're Not Too Worried About Luxxu Group's (HKG:1327) Cash Burn Situation